Search results for "Cardia"

showing 10 items of 2767 documents

Protrhombotic Effects of Contraceptives

2010

The use of oral contraceptives first became widespread some 40 years ago, and reports of an excess risk of cardiovascular disease among women who used these agents soon followed. Few drugs have been the object of such intensive epidemiological research, the outcome of which has provided clinicians with detailed information about risks not only of specific thrombotic diseases but also important non-contraceptive benefits from the pill. Recently, oral contraceptives have been classified by some according to "generation" (first, second, third, and most recently, fourth generation): first-generation formulations containing lynestrenol or norethindrone, second-generation formulations containing …

medicine.medical_specialtymedicine.drug_classLipid Metabolism DisordersMyocardial InfarctionPhysiologyGestodeneRisk AssessmentRisk FactorsDesogestrelInternal medicineDrug DiscoverymedicineHumansLevonorgestrelGlucose Metabolism DisordersVenous ThrombosisPharmacologyHemostasisbusiness.industryModels CardiovascularAtherosclerosisLipid MetabolismNorgestimateSettore MED/11 - Malattie Dell'Apparato CardiovascolareLynestrenolEndocrinologyEstrogenPillHypertensionFemaleRisk assessmentbusinessTrhombosis contraceptivesContraceptives Oralmedicine.drugCurrent Pharmaceutical Design
researchProduct

Papel de la antitrombina iii en cirugía cardiaca

2013

Coagulation of blood is of multidisciplinary interest. Cardiac surgery produces major changes in the delicate balance between pro-and anti-coagulant serum factors. The role of antithrombin iii has been analysed after finding evidence that associated decreased levels of protein activity to postoperative morbidity and mortality. Supplementing exogenous antithrombin is considered with the aim of optimising outcomes. Its intrinsic anticoagulant and anti-inflammatory properties have stimulated a growing interest, and suggests new lines of research.

medicine.medical_specialtymedicine.drug_classbusiness.industryAnticoagulantAntithrombinCritical Care and Intensive Care MedicineCardiac surgeryAnesthesiology and Pain MedicineCoagulationInternal medicinemedicineCardiologyProtein activitybusinessmedicine.drugRevista Española de Anestesiología y Reanimación
researchProduct

Type 1 or Type 2 Myocardial Infarction in Patients with a History of Coronary Artery Disease: Data from the Emergency Department

2019

A type 2 myocardial infarction (T2MI) is the result of an imbalance between oxygen supply and demand, without acute atherothrombosis. T2MI is frequent in emergency departments (ED), but has not been extensively evaluated in patients with previously known coronary artery disease (CAD). Our study assessed the incidence and characteristics of T2MI compared to type 1 (T1MI) in CAD patients admitted to an ED. Among 33,669 consecutive patients admitted to the ED, 2830 patients with T1MI or T2MI were systematically included after prospective adjudication by the attending clinician according to the universal definition. Among them, 619 (22%) patients had a history of CAD. Using multivariable analys…

medicine.medical_specialtymedicine.medical_treatment030204 cardiovascular system & hematologyArticletype 2 myocardial infarctionCoronary artery disease03 medical and health sciences0302 clinical medicineInternal medicinemedicine030212 general & internal medicineMyocardial infarctionhospital mortalitybiologybusiness.industryC-reactive proteinPercutaneous coronary interventionGeneral MedicineOdds ratioEmergency departmentmedicine.diseaseTroponinConfidence intervalmyocardial infarctionCardiologybiology.proteinbusinesscoronary artery diseaseJournal of Clinical Medicine
researchProduct

Impact of overlapping on 1-year clinical outcomes in patients undergoing everolimus-eluting bioresorbable scaffolds implantation in routine clinical …

2016

Background Overlapping implantation of bioresorbable scaffolds (BRSs) are frequent in long coronary lesions. Its impact on clinical outcomes is unknown. Objective: To compare the clinical outcomes of patients treated with overlapping BRS with those patients treated with no-overlap BRS. Methods: We analyzed the 1-year clinical outcomes of 1,477 patients treated with BRS in the GHOST-EU registry, according to the implantation of overlapping BRS. Primary endpoint was patient oriented composite endpoint (PoCE) of: all-cause death, any myocardial infarction (MI) and any repeated revascularization. Scaffold thrombosis, according to Academic Research Consortium definition, was also analyzed. Resul…

medicine.medical_specialtymedicine.medical_treatment030204 cardiovascular system & hematologyRevascularizationCoronary artery diseaseLesion03 medical and health sciences0302 clinical medicineInternal medicinemedicineClinical endpointRadiology Nuclear Medicine and imaging030212 general & internal medicineMyocardial infarctionEverolimusbusiness.industryfungiPercutaneous coronary interventionGeneral Medicinemedicine.diseaseThrombosisCardiologymedicine.symptomCardiology and Cardiovascular Medicinebusinessmedicine.drugCatheterization and Cardiovascular Interventions
researchProduct

Update on Brugada Syndrome 2019

2021

Brugada syndrome (BrS) was first described in 1992 as an aberrant pattern of ST segment elevation in right precordial leads with a high incidence of sudden cardiac death (SCD) in patients with structurally normal heart. It represents 4% ∼ 12% of all SCD and 20% of SCD in patients with structurally normal heart. The extremely wide genetic heterogeneity of BrS and other inherited cardiac disorders makes this new area of genetic arrhytmology a fascinating one. This review shows the state of art in diagnosis, management, and treatment of BrS focusing all the aspects regarding genetics and Preimplant Genetic Diagnosis (PGD) of embryos, overlapping syndromes, risk stratification, familial screeni…

medicine.medical_specialtymedicine.medical_treatment030204 cardiovascular system & hematologyRisk Assessmentsudden cardiac deathSudden cardiac deathElectrocardiography03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansST segmentBrugada syndromeIn patient030212 general & internal medicineCardiac disordersBrugada syndromeMedicine(all)business.industryGenetic heterogeneityGeneral Medicinemedicine.diseaseImplantable cardioverter-defibrillatorBrugada Syndrome.Defibrillators ImplantableCardiologyhigh incidenceCardiology and Cardiovascular MedicinebusinessRisk assessmentCurrent Problems in Cardiology
researchProduct

Non-responders to cardiac resynchronization therapy: Insights from multimodality imaging and electrocardiography. A brief review

2016

Background Cardiac resynchronization therapy (CRT) is a successful strategy for heart failure (HF) patients. The pre-requisite for the response is the evidence of electrical dyssynchrony on the surface electrocardiogram usually as left bundle branch block (LBBB). Non-response to CRT is a significant problem in clinical practice. Patient selection, inadequate delivery and sub-optimal left ventricle lead position may be important causes. Objectives In an effort to improve CRT response multimodality imaging (especially echocardiography, computed tomography and cardiac magnetic resonance) could play a decisive role and extensive literature has been published on the matter. However, we are so fa…

medicine.medical_specialtymedicine.medical_treatmentCardiac resynchronization therapyHeart failure030204 cardiovascular system & hematologyMultimodal ImagingMultimodality imagingMultimodalityCardiac Resynchronization TherapyElectrocardiography03 medical and health sciencesQRS complex0302 clinical medicineInternal medicinemedicineHumans030212 general & internal medicineResponse rate (survey)medicine.diagnostic_testbusiness.industryLeft bundle branch blockMedicine (all)Responsemedicine.diseaseTreatment Outcomemedicine.anatomical_structureCardiac resynchonization therapyVentricleHeart failurecardiovascular systemCardiologyRadiologyCardiology and Cardiovascular MedicinebusinessElectrocardiographyInternational Journal of Cardiology
researchProduct

Management of refractory angina: an update.

2020

Abstract Despite the use of anti-anginal drugs and/or percutaneous coronary interventions (PCI) or coronary artery bypass grafting, the proportion of patients with coronary artery disease who have daily or weekly angina ranges from 2% to 24%. Refractory angina refers to long-lasting symptoms (for >3 months) due to established reversible ischaemia, which cannot be controlled by escalating medical therapy with the use of 2nd- and 3rd-line pharmacological agents, bypass grafting, or stenting. While there is uncertain prognostic benefit, the treatment of refractory angina is important to improve the quality of life of the patients affected. This review focuses on conventional pharmacolog…

medicine.medical_specialtymedicine.medical_treatmentChronic coronary syndromeStemcell therapyCoronary Artery Disease030204 cardiovascular system & hematologyRevascularizationAngina PectorisAnginaCoronary artery disease03 medical and health sciencesCoronary artery bypass surgery0302 clinical medicinePercutaneous Coronary InterventionRestenosisInternal medicinemedicineMyocardial RevascularizationHumanscardiovascular diseases030212 general & internal medicineCoronary Artery BypassCoronary sinusbusiness.industryPercutaneous coronary interventionAnginamedicine.diseaseRadiation therapyChronic total occlusionSpinal cord stimulationConventional PCICardiologyQuality of LifeCardiology and Cardiovascular MedicinebusinessEuropean heart journal
researchProduct

Cardiac pacemaker function of HCN4 channels in mice is confined to embryonic development and requires cyclic AMP.

2008

Important targets for cAMP signalling in the heart are hyperpolarization-activated and cyclic nucleotide-gated (HCN) channels that underlie the depolarizing 'pacemaker' current, I(f). We studied the role of I(f) in mice, in which binding of cAMP to HCN4 channels was abolished by a single amino-acid exchange (R669Q). Homozygous HCN4(R669Q/R669Q) mice die during embryonic development. Prior to E12, homozygous and heterozygous embryos display reduced heart rates and show no or attenuated responses to catecholaminergic stimulation. Adult heterozygous mice display normal heart rates at rest and during exercise. However, following beta-adrenergic stimulation, hearts exhibit pauses and sino-atrial…

medicine.medical_specialtymedicine.medical_treatmentCyclic Nucleotide-Gated Cation ChannelsEmbryonic DevelopmentStimulationMice TransgenicBiologyIn Vitro TechniquesGeneral Biochemistry Genetics and Molecular BiologyCardiac pacemakerArticleMiceHeart RatePregnancyInternal medicineHeart ratemedicineCyclic AMPHyperpolarization-Activated Cyclic Nucleotide-Gated ChannelsAnimalsMyocytes CardiacMolecular BiologyIon channelCells CulturedCatecholaminergicGeneral Immunology and MicrobiologyGeneral NeuroscienceEmbryogenesisDepolarizationEmbryoHeartMice Inbred C57BLEndocrinologyMutationFemaleThe EMBO journal
researchProduct

Treatment decision making in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy: State of the art

2014

No abstract available

medicine.medical_specialtymedicine.medical_treatmentDecision MakingCardiomyopathySudden deathImplantable cardioverter-defibrillatorAntiarrhythmic drugs; Cardiac transplantation; Implantable cardioverter-defibrillator; Management; Radiofrequency catheter ablation; Sudden death; Arrhythmogenic Right Ventricular Dysplasia; Decision Making; HumansAntiarrhythmic drugs; Cardiac transplantation; Implantable cardioverter-defibrillator; Management; Radiofrequency catheter ablation; Sudden deathInternal medicinemedicineHumansIn patientIntensive care medicineArrhythmogenic Right Ventricular DysplasiaRadiofrequency catheter ablationbusiness.industrySudden deathImplantable cardioverter-defibrillatormedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareArrhythmogenic right ventricular dysplasiaAntiarrhythmic drugsManagementAntiarrhythmic drugRadiofrequency catheter ablationCardiologyCardiac transplantationTreatment decision makingCardiology and Cardiovascular Medicinebusiness
researchProduct

Invasive Versus Conservative Strategy in Frail Patients With NSTEMI: The MOSCA-FRAIL Clinical Trial Study Design

2019

Abstract Introduction and objectives Although clinical guidelines recommend invasive management in non–ST-segment elevation myocardial infarction (NSTEMI), this strategy is underused in frail elderly patients in the real world. Furthermore, these patients are underrepresented in clinical trials and therefore the evidence is scarce. Our hypothesis is that an invasive strategy will improve prognosis in elderly frail patients with NSTEMI . Methods This will be a prospective, multicenter, randomized trial, in which the conservative and invasive strategies will be compared in patients meeting all of the following inclusion criteria: NSTEMI diagnosis, age ≥ 70 years, and frailty defined by a cate…

medicine.medical_specialtymedicine.medical_treatmentFrail ElderlyAcute myocardial infarction030204 cardiovascular system & hematologyRevascularizationConservative TreatmentCoronary Angiographylaw.invention03 medical and health sciences0302 clinical medicineElderlyRandomized controlled triallawmedicineClinical endpointMyocardial RevascularizationHumansMulticenter Studies as TopicFrail elderlyMyocardial infarctionProspective StudiesProspective cohort studyNon-ST Elevated Myocardial InfarctionAgedRandomized Controlled Trials as TopicFrailtybusiness.industryGeneral Medicinemedicine.diseaseClinical trialTreatment OutcomeSample size determinationSample SizeEmergency medicinebusiness
researchProduct